These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
200 related articles for article (PubMed ID: 23640069)
1. Developmental therapeutics in acute myelogenous leukemia: are there any new effective cytotoxic chemotherapeutic agents out there? Mims A; Stuart RK Curr Hematol Malig Rep; 2013 Jun; 8(2):156-62. PubMed ID: 23640069 [TBL] [Abstract][Full Text] [Related]
2. The role of small molecule Flt3 receptor protein-tyrosine kinase inhibitors in the treatment of Flt3-positive acute myelogenous leukemias. Roskoski R Pharmacol Res; 2020 May; 155():104725. PubMed ID: 32109580 [TBL] [Abstract][Full Text] [Related]
3. Is targeted therapy feasible in acute myelogenous leukemia? Konig H; Levis M Curr Hematol Malig Rep; 2014 Jun; 9(2):118-27. PubMed ID: 24599573 [TBL] [Abstract][Full Text] [Related]
5. Midostaurin in Combination With Standard Chemotherapy for Treatment of Newly Diagnosed FMS-Like Tyrosine Kinase 3 (FLT3) Mutation-Positive Acute Myeloid Leukemia. Kim M; Williams S Ann Pharmacother; 2018 Apr; 52(4):364-369. PubMed ID: 29231051 [TBL] [Abstract][Full Text] [Related]
6. The Development of FLT3 Inhibitors in Acute Myeloid Leukemia. Garcia JS; Stone RM Hematol Oncol Clin North Am; 2017 Aug; 31(4):663-680. PubMed ID: 28673394 [TBL] [Abstract][Full Text] [Related]